Background & aim: Unilateral ureteral obstruction (UUO) is a widely used preclinical model of surgery-induced chronic kidney disease characterized by robust inflammation and tubulointerstitial fibrosis. However, the temporal relationship between tubular injury, inflammatory responses, fibrotic remodeling, and associated transcriptional changes…
Background & aim: Two-dimensional (2D) histopathology is the current gold-standard for assessing toxicology in ovaries. However, it can be a time-consuming process limited by section-to section variability, subjective interpretation and sampling bias. To overcome these limitations, we have developed a…
Background & aim: Efficient delivery of anti-β-amyloid (Aβ) antibodies across the blood–brain barrier (BBB) remains a central challenge in Alzheimer’s disease (AD) therapy. Therapeutic Aβ-targeted antibodies engineered for receptor-mediated transcytosis display improved brain exposure and therapeutic efficacy, yet their brain-wide…
Background & aim: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown promise in preclinical models of neurodegeneration, with emerging evidence suggesting these effects may be driven by modulation of neuroinflammation. However, the cellular mechanisms underlying GLP-1RA effects on neuroinflammation remain poorly…
Background & aim: Accurate assessment of glomerulosclerosis is essential for diagnosis, prognosis, and treatment of kidney diseases. Here, we developed a deep learning–based scoring method for glomerulosclerosis in PAS-stained kidney tissue. Additionally, we implemented an AI-based compartmental analysis to evaluate how…
Background & aim: Chronic myocardial injury over weeks to months drives cellular hypertrophy and extracellular matrix remodeling, culminating in heart failure with preserved ejection fraction (HFpEF). Traditional 2D histological sectioning may miss or misrepresent the true spatial heterogeneity of localized…
Background & aim: Translational models are essential to identify improved treatment options for chronic kidney disease (CKD) patients. However, most preclinical CKD models do not demonstrate reduced glomerular filtration rate (GFR) or improvement by standard of care (SoC). The aim…
Background & aim: Bulk RNA-sequencing has limited cellular-level insight into metabolic-associated steatohepatitis (MASH) and its progression to hepatocellular carcinoma (HCC) by masking rare and tumor-relevant populations. Here, we used single-cell transcriptomics to characterize liver cell-specific transcriptomic changes in the GAN…
Background & aim: Fibroblast growth factor 21 (FGF21) plays a key role in hepatic lipid metabolism and holds great promise as therapeutic target for metabolic dysfunctionassociated steatohepatitis (MASH). Efruxifermin (EFX) is a long acting FGF21 analogue currently in phase 3…
